SLS
Closed
Sellas Life Sciences Group Inc
2.08
-0.11 (-5.02%)
Last Update: 01 Jul 2025 23:08:00
Yesterday: 2.19
Day's Range: 2.05 - 2.18
Send
sign up or login to leave a comment!
When Written:
1.49
Sellas Life Sciences Group Inc. is a clinical-stage biopharmaceutical company that focuses on the development of cancer immunotherapies. The company's lead product candidate, galinpepimut-S (GPS), is a cancer vaccine designed to stimulate the immune system to attack cancer cells. GPS is being developed for the treatment of acute myeloid leukemia (AML) and malignant pleural mesothelioma (MPM).
Sellas Life Sciences Group Inc. was founded in 2012 and is headquartered in New York City. The company is listed on the NASDAQ stock exchange under the ticker symbol "SLS".
In addition to GPS, Sellas Life Sciences Group Inc. has a pipeline of other cancer immunotherapy candidates, including nelipepimut-S (NPS), which is being developed for the treatment of triple-negative breast cancer.
Sellas Life Sciences Group Inc. has partnerships with various academic institutions and research organizations, including Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, and the National Cancer Institute. The company has also received funding from the National Institutes of Health and the Leukemia & Lymphoma Society.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Sellas Life Sciences Group Inc. was founded in 2012 and is headquartered in New York City. The company is listed on the NASDAQ stock exchange under the ticker symbol "SLS".
In addition to GPS, Sellas Life Sciences Group Inc. has a pipeline of other cancer immunotherapy candidates, including nelipepimut-S (NPS), which is being developed for the treatment of triple-negative breast cancer.
Sellas Life Sciences Group Inc. has partnerships with various academic institutions and research organizations, including Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, and the National Cancer Institute. The company has also received funding from the National Institutes of Health and the Leukemia & Lymphoma Society.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








